Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David W Cescon

Showing results (121-130 of 133) with videos related to

Pageof 14
Sort By:
Hepatology (Baltimore, Md.)|March 18, 2022
Polo-like kinase 4 inhibitor CFI-400945 suppresses liver cancer through cell cycle perturbation and eliciting antitumor immunityCerise Yuen-Ki Chan, Vincent Wai-Hin Yuen, David Kung-Chun Chiu, et al.
Cancer Cell|January 27, 2015
Glutathione and thioredoxin antioxidant pathways synergize to drive cancer initiation and progressionIsaac S Harris, Aislinn E Treloar, Satoshi Inoue, et al.
JCO Precision Oncology|August 17, 2022
Clinical Activity of Mitogen-Activated Protein Kinase-Targeted Therapies in Patients With Non-V600 BRAF-Mutant TumorsMatthew Dankner, Yifan Wang, Rouhi Fazelzad, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 9, 2019
AhR controls redox homeostasis and shapes the tumor microenvironment in BRCA1-associated breast cancerShawn P Kubli, Christian Bassi, Cecilia Roux, et al.
Nature Chemical Biology|May 16, 2022
PRMT inhibition induces a viral mimicry response in triple-negative breast cancerQin Wu, David Y Nie, Wail Ba-Alawi, et al.
Nature Communications|August 23, 2020
GLUT1 inhibition blocks growth of RB1-positive triple negative breast cancerQin Wu, Wail Ba-Alawi, Genevieve Deblois, et al.
Nature Communications|January 3, 2026
Binimetinib and encorafenib for the treatment of advanced solid tumors with non-V600E BRAF mutations: results from the Phase II BEAVER trialApril A N Rose, Jennifer Maxwell, Emmanuelle Rousselle, et al.
Nature Communications|June 24, 2022
Results of the phase I CCTG IND.231 trial of CX-5461 in patients with advanced solid tumors enriched for DNA-repair deficienciesJohn Hilton, Karen Gelmon, Philippe L Bedard, et al.
JNCI Cancer Spectrum|April 28, 2020
Toronto Workshop on Late Recurrence in Estrogen Receptor-Positive Breast Cancer: Part 2: Approaches to Predict and Identify Late Recurrence, Research DirectionsRyan J O Dowling, Joseph A Sparano, Pamela J Goodwin, et al.
JNCI Cancer Spectrum|April 28, 2020
Toronto Workshop on Late Recurrence in Estrogen Receptor-Positive Breast Cancer: Part 1: Late Recurrence: Current Understanding, Clinical ConsiderationsRyan J O Dowling, Kevin Kalinsky, Daniel F Hayes, et al.
Pageof 14

Showing results (121-130 of 133) with videos related to

Sort By:
Pageof 14
Hepatology (Baltimore, Md.)|March 18, 2022
Polo-like kinase 4 inhibitor CFI-400945 suppresses liver cancer through cell cycle perturbation and eliciting antitumor immunityCerise Yuen-Ki Chan, Vincent Wai-Hin Yuen, David Kung-Chun Chiu, et al.
Cancer Cell|January 27, 2015
Glutathione and thioredoxin antioxidant pathways synergize to drive cancer initiation and progressionIsaac S Harris, Aislinn E Treloar, Satoshi Inoue, et al.
JCO Precision Oncology|August 17, 2022
Clinical Activity of Mitogen-Activated Protein Kinase-Targeted Therapies in Patients With Non-V600 BRAF-Mutant TumorsMatthew Dankner, Yifan Wang, Rouhi Fazelzad, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 9, 2019
AhR controls redox homeostasis and shapes the tumor microenvironment in BRCA1-associated breast cancerShawn P Kubli, Christian Bassi, Cecilia Roux, et al.
Nature Chemical Biology|May 16, 2022
PRMT inhibition induces a viral mimicry response in triple-negative breast cancerQin Wu, David Y Nie, Wail Ba-Alawi, et al.
Nature Communications|August 23, 2020
GLUT1 inhibition blocks growth of RB1-positive triple negative breast cancerQin Wu, Wail Ba-Alawi, Genevieve Deblois, et al.
Nature Communications|January 3, 2026
Binimetinib and encorafenib for the treatment of advanced solid tumors with non-V600E BRAF mutations: results from the Phase II BEAVER trialApril A N Rose, Jennifer Maxwell, Emmanuelle Rousselle, et al.
Nature Communications|June 24, 2022
Results of the phase I CCTG IND.231 trial of CX-5461 in patients with advanced solid tumors enriched for DNA-repair deficienciesJohn Hilton, Karen Gelmon, Philippe L Bedard, et al.
JNCI Cancer Spectrum|April 28, 2020
Toronto Workshop on Late Recurrence in Estrogen Receptor-Positive Breast Cancer: Part 2: Approaches to Predict and Identify Late Recurrence, Research DirectionsRyan J O Dowling, Joseph A Sparano, Pamela J Goodwin, et al.
JNCI Cancer Spectrum|April 28, 2020
Toronto Workshop on Late Recurrence in Estrogen Receptor-Positive Breast Cancer: Part 1: Late Recurrence: Current Understanding, Clinical ConsiderationsRyan J O Dowling, Kevin Kalinsky, Daniel F Hayes, et al.
Pageof 14